EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors

Hiddo J L Heerspink iD, Irene L Noronha iD, Jose Luis Górriz iD, Soo Kun Lim iD, Sradha S Kotwal iD, Gianna M Kirsztajn iD, José Barros Neto iD, Jessica Ryan iD, Mei Sian Fu, Sung-Gyun Kim iD, Jonathan Barratt iD, Yasmin Brahmbhatt und 6 weitere

Journal of the American Society of Nephrology · 2026

DOI: 10.1681/asn.0000001076 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Society of Nephrology, 2026. Verfasst von Hiddo J L Heerspink und 17 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Atrasentan, Sodium-Glucose Transporter 2 Inhibitors, Pyrrolidines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Patients with IgA nephropathy and proteinuria are at risk of kidney failure despite use of guideline-recommended renin-angiotensin system and sodium-glucose cotransporter 2 (SGLT2) inhibition. Atrasentan reduces proteinuria in IgA nephropathy, but its efficacy as adjunct to renin-angiotensin system and SGLT2 inhibition has not been rigorously tested. Atrasentan provided a clinically meaningful reduction in proteinuria in adults with IgA nephropathy treated with renin-angiotensin system and SGLT2 inhibitors.

Background

Atrasentan, a highly selective endothelin-A receptor antagonist, is approved for proteinuria reduction in adults with IgA nephropathy. Renin-angiotensin system inhibitors (RASi) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are guideline recommended, yet the additional benefit of atrasentan has not been rigorously determined.

Methods

We performed a randomized, double-blind, placebo-controlled crossover study of atrasentan in adults with IgA nephropathy, eGFR ≥30 ml/min per 1.73 m 2 , and urinary protein >0.5 g/d while on maximal, stable RASi and SGLT2i. Participants were randomized 1:1 to either sequence AB or sequence BA (0.75 mg atrasentan [A] once daily during period 1 and matching placebo [B] during period 2, or vice versa), with a 12-week washout period in between. The primary end point was the change in urinary protein-to-creatinine ratio (UPCR) to week 12. The secondary end point was the change in UPCR to week 24. Safety end points included the type, incidence, severity, seriousness, and relatedness of adverse events (AEs).

Results

We recruited 54 participants with mean age 48 years (SD 12), 43% female, mean (SD) eGFR 63 (22) ml/min per 1.73 m 2 , and median UPCR 1.0 g/g (Q1–Q3, 0.7–1.4). Treatment with atrasentan versus placebo resulted in a difference in geometric mean percentage change in UPCR at week 12 of −25.3% (95% confidence interval, −36.8 to −11.7; P < 0.001). The treatment difference in UPCR between atrasentan versus placebo during treatment period 2 at week 24 was −26.4% (95% confidence interval, −45.8 to −0.0). There was one unrelated serious adverse event. Fluid retention events were uncommon, and none required hospitalization. There were no study drug discontinuations due to treatment-related adverse events and no deaths.

Conclusions

Atrasentan provided a clinically meaningful reduction in proteinuria in adults with IgA nephropathy and proteinuria ≥0.5 g/d treated with RASi and SGLT2i therapy. Atrasentan was well tolerated, and no new safety signals emerged. Clinical Trial registry name and registration number: NCT05834738.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAAtrasentanSodium-Glucose Transporter 2 InhibitorsPyrrolidinesEndothelin A Receptor AntagonistsHumansCross-Over StudiesFemaleAdultMaleDouble-Blind MethodMiddle AgedProteinuriaTreatment Outcome

Stichwörter der Autor:innen

CKDGNIgA nephropathySGLT2 inhibitorsclinical nephrologyclinical trialglomerular diseasekidney diseaseproteinuria

Substanzen

AtrasentanSodium-Glucose Transporter 2 InhibitorsPyrrolidinesEndothelin A Receptor Antagonists

Autor:innen und Institutionen

  • The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Renal Division, University of São Paulo Medical School, São Paulo, Brazil.
  • Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
  • Universidad de Valencia, Valencia, Spain.
  • Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

ORCID-Profile: Hiddo J L Heerspink, Irene L Noronha, Jose Luis Górriz, Soo Kun Lim, Sradha S Kotwal, Gianna M Kirsztajn, José Barros Neto, Jessica Ryan, Sung-Gyun Kim, Jonathan Barratt, Greggory J Housler, Marion Dahlke, Amy K Mottl

Förderung

  • Novartis

Zitieren

APA

Heerspink, H. J. L., Noronha, I. L., Górriz, J. L., Lim, S. K., Kotwal, S. S., Kirsztajn, G. M., Barros Neto, J., Ryan, J., Fu, M. S., Kim, S. G., Barratt, J., Brahmbhatt, Y., Housler, G. J., Jiao, R., Dahlke, M., Lodha, A., Mottl, A. K., & Atrasentan and Sodium Glucose Cotransporter-2 Inhibitor Efficacy and Safety Trial (ASSIST) Investigator Group (2026). Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001076

Vancouver

Heerspink HJL, Noronha IL, Górriz JL, Lim SK, Kotwal SS, Kirsztajn GM, et al. Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001076

BibTeX
@article{Heerspink2026,
  author = {Heerspink, Hiddo J L and Noronha, Irene L and Górriz, Jose Luis and Lim, Soo Kun and Kotwal, Sradha S and Kirsztajn, Gianna M and Barros Neto, José and Ryan, Jessica and Fu, Mei Sian and Kim, Sung-Gyun and Barratt, Jonathan and Brahmbhatt, Yasmin and Housler, Greggory J and Jiao, Rong and Dahlke, Marion and Lodha, Amit and Mottl, Amy K and Atrasentan and Sodium Glucose Cotransporter-2 Inhibitor Efficacy and Safety Trial (ASSIST) Investigator Group, Atrasentan and Sodium Glucose Cotransporter-2 Inhibitor Efficacy and Safety Trial (ASSIST) Investigator Group},
  title = {Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001076}
}
Kostenlos starten →